- With this approval, Benuvia has begun focusing on four primary psychedelic ingredients: Psilocybin, N,N-Dimethyl-5-Methoxy-Tryptamine (5-MeO DMT), Dimethyltryptamine (DMT), and 3,4-Methylenedioxymethamphetamine, or MDMA
- Benuvia will manufacture psychedelic APIs in its 83,000 square foot manufacturing facility that is permitted by the US DEA for Schedule I to III Controlled Substances, and is FDA registered and a cGMP facility
- Benuvia is positioning itself to become a leading global supplier of psychedelic active pharmaceutical ingredients (APIs), complementing its established portfolio of cannabinoid APIs
ROUND ROCK, Texas, May 16, 2022 /PRNewswire/ -- Benuvia, Inc., a drug developer and manufacturer of APIs focused on cannabinoids, with...
- 承認された後,Benuviaはヌードゲラジン,N,N−ジメチル−5−メトキシアミン(5−MeO DMT),ジメチルクロラミン(DMT)および3,4−メチレンジオキシメチルフェニルプロピルアミン,または...